Sino BiologicalInc.
Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discover… Read more
Sino BiologicalInc. (301047) - Net Assets
Latest net assets as of June 2025: CN¥5.73 Billion CNY
Based on the latest financial reports, Sino BiologicalInc. (301047) has net assets worth CN¥5.73 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.94 Billion) and total liabilities (CN¥205.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.73 Billion |
| % of Total Assets | 96.54% |
| Annual Growth Rate | 107.51% |
| 5-Year Change | 344.53% |
| 10-Year Change | N/A |
| Growth Volatility | 313.04 |
Sino BiologicalInc. - Net Assets Trend (2019–2024)
This chart illustrates how Sino BiologicalInc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sino BiologicalInc. (2019–2024)
The table below shows the annual net assets of Sino BiologicalInc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.77 Billion | -9.33% |
| 2023-12-31 | CN¥6.37 Billion | -0.03% |
| 2022-12-31 | CN¥6.37 Billion | -5.68% |
| 2021-12-31 | CN¥6.75 Billion | +419.95% |
| 2020-12-31 | CN¥1.30 Billion | +766.88% |
| 2019-12-31 | CN¥149.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sino BiologicalInc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1382.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.24 Billion | 21.40% |
| Other Components | CN¥4.54 Billion | 78.60% |
| Total Equity | CN¥5.77 Billion | 100.00% |
Sino BiologicalInc. Competitors by Market Cap
The table below lists competitors of Sino BiologicalInc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Career International Co Ltd
SHE:300662
|
$400.92 Million |
|
Helgeland Sparebank
OL:HELG
|
$400.97 Million |
|
TRI CHEMICAL LABORAT.INC.
F:22E
|
$400.98 Million |
|
Lindian Resources Ltd
AU:LIN
|
$401.00 Million |
|
PSG Corp. PCL
BK:PSG
|
$400.54 Million |
|
Yan Tai Shuang Ta Food Co Ltd
SHE:002481
|
$400.18 Million |
|
Pansoft Company Limited
SHE:300996
|
$400.16 Million |
|
Chromadex Corp
NASDAQ:CDXC
|
$400.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sino BiologicalInc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,366,982,289 to 5,772,912,132, a change of -594,070,157 (-9.3%).
- Net income of 121,927,677 contributed positively to equity growth.
- Dividend payments of 255,520,782 reduced retained earnings.
- Other factors decreased equity by 460,477,052.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥121.93 Million | +2.11% |
| Dividends Paid | CN¥255.52 Million | -4.43% |
| Other Changes | CN¥-460.48 Million | -7.98% |
| Total Change | CN¥- | -9.33% |
Book Value vs Market Value Analysis
This analysis compares Sino BiologicalInc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 46.21x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥1.55 | CN¥71.44 | x |
| 2020-12-31 | CN¥13.40 | CN¥71.44 | x |
| 2021-12-31 | CN¥52.26 | CN¥71.44 | x |
| 2022-12-31 | CN¥49.30 | CN¥71.44 | x |
| 2023-12-31 | CN¥49.28 | CN¥71.44 | x |
| 2024-12-31 | CN¥47.46 | CN¥71.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sino BiologicalInc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.87%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.05x
- Recent ROE (2.11%) is below the historical average (22.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 24.31% | 20.14% | 0.97x | 1.25x | CN¥21.43 Million |
| 2020 | 86.83% | 70.64% | 1.07x | 1.15x | CN¥997.74 Million |
| 2021 | 10.66% | 74.59% | 0.14x | 1.02x | CN¥44.78 Million |
| 2022 | 4.76% | 52.72% | 0.09x | 1.03x | CN¥-333.95 Million |
| 2023 | 4.09% | 40.24% | 0.10x | 1.04x | CN¥-376.57 Million |
| 2024 | 2.11% | 19.87% | 0.10x | 1.05x | CN¥-455.36 Million |
Industry Comparison
This section compares Sino BiologicalInc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sino BiologicalInc. (301047) | CN¥5.73 Billion | 24.31% | 0.04x | $400.87 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |